NCT00101400View on ClinicalTrials.gov

BAY43-9006 - Phase II in Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2008

Conditions

Breast NeoplasmsBreast Cancer

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib 400 mg administered twice daily (b.i.d.)

Trial Locations (7)

20133

Milan

20162

Milan

40138

Bologna

43100

Parma

60590

Frankfurt am Main

70199

Stuttgart

80637

München

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY